Core Insights - Niagen Bioscience Inc. reported strong financial performance for 2025, with net revenue of $129.4 million, reflecting a 30% year-over-year growth, and a net income of $17.4 million [5][25][30] - The company is well-positioned for 2026, despite increased competition in the NAD market, and continues to lead in NAD science with significant research backing [6][13] - The company has secured a patent for NIAGEN Plus, which will expand its product offerings into intravenous and injectable formulations, and plans to launch at-home injection kits in 2026 [8][9] Financial Performance - In Q4 2025, revenue reached $33.8 million, a 16% increase from the previous year, driven primarily by e-commerce sales [5][27] - Gross margin improved to 64.3% for the full year, indicating enhanced operational efficiency [25] - Selling and marketing expenses were 30.8% of sales in Q4, reflecting targeted investments in brand awareness [29] Research and Development - Niagen Bioscience Inc. remains the global leader in NAD science, with 29 studies published since the last earnings call, including clinical studies demonstrating the benefits of nicotinamide riboside (NR) [6][15] - Notable studies include findings that NR supplementation can slow aging and improve fatigue, sleep quality, and cognitive function [7][16][20] - The company is focusing on the therapeutic potential of NR in neurodegenerative diseases, including ongoing collaborations to explore its preventive effects in Parkinson's disease [18][57] Product Development and Market Expansion - The company plans to expand its presence in the beauty and cosmetics market, following the successful launch of Tru Niagen in beauty [9][46] - Niagen Plus will be introduced in over 1,200 health clinics, with plans to partner with telehealth providers for distribution [8][9] - The company is also exploring new retail channels and international markets, particularly in Asia and the EU [46] Legal and Regulatory Environment - Niagen Bioscience Inc. is currently involved in litigation against the FDA regarding the marketing of NMN as a dietary supplement, believing it has a strong case [10][55] - The company has acquired patents for multiple NR salt forms, enhancing its intellectual property portfolio and market position [11]